# Eikon Therapeutics, Inc.: financial statements, quarterly

EIKN · Nasdaq · CIK 1861123 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eikn.md) · [Financials](/companies/eikn/financials.md) · [Filings](/companies/eikn/filings.md) · [Insiders](/companies/eikn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eikn/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | [56.6](/filings/0001193125-26-216791.md) | [69.2](/filings/0001193125-26-349185.md) | [70.0](/filings/0001193125-26-216791.md) | [75.5](/filings/0001193125-26-349185.md) |
| Operating income | $m | [(71.4)](/filings/0001193125-26-216791.md) | [(110)](/filings/0001193125-26-349185.md) | [(87.3)](/filings/0001193125-26-216791.md) | [(93.4)](/filings/0001193125-26-349185.md) |
| Net income | $m | [(68.2)](/filings/0001193125-26-349185.md) | [(105)](/filings/0001193125-26-349185.md) | [(83.0)](/filings/0001193125-26-349185.md) | [(88.4)](/filings/0001193125-26-349185.md) |
| Diluted EPS | $ per share | [(26.91)](/filings/0001193125-26-216791.md) | [(36.94)](/filings/0001193125-26-349185.md) | [(2.46)](/filings/0001193125-26-216791.md) | [(1.63)](/filings/0001193125-26-349185.md) |
| Basic EPS | $ per share | [(26.91)](/filings/0001193125-26-216791.md) | [(36.94)](/filings/0001193125-26-349185.md) | [(2.46)](/filings/0001193125-26-216791.md) | [(1.63)](/filings/0001193125-26-349185.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [205](/filings/0001193125-26-216791.md) | [137](/filings/0001193125-26-349185.md) | [105](/filings/0001193125-26-349185.md) | [161](/filings/0001193125-26-216791.md) | [143](/filings/0001193125-26-349185.md) |
| Current assets | $m | not reported | not reported | not reported | [349](/filings/0001193125-26-349185.md) | [530](/filings/0001193125-26-216791.md) | [547](/filings/0001193125-26-349185.md) |
| Total assets | $m | not reported | not reported | not reported | [595](/filings/0001193125-26-349185.md) | [851](/filings/0001193125-26-216791.md) | [780](/filings/0001193125-26-349185.md) |
| Current liabilities | $m | not reported | not reported | not reported | [55.0](/filings/0001193125-26-349185.md) | [45.1](/filings/0001193125-26-216791.md) | [55.3](/filings/0001193125-26-349185.md) |
| Total liabilities | $m | not reported | not reported | not reported | [312](/filings/0001193125-26-349185.md) | [300](/filings/0001193125-26-216791.md) | [313](/filings/0001193125-26-349185.md) |
| Shareholders' equity | $m | [(572)](/filings/0001193125-26-349185.md) | [(640)](/filings/0001193125-26-349185.md) | [(738)](/filings/0001193125-26-349185.md) | [(879)](/filings/0001193125-26-349185.md) | [551](/filings/0001193125-26-349185.md) | [467](/filings/0001193125-26-349185.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(54.5)](/filings/0001193125-26-216791.md) | [(32.7) d](/filings/0001193125-26-349185.md) | [(89.8)](/filings/0001193125-26-216791.md) | [(65.0) d](/filings/0001193125-26-349185.md) |
| Capital expenditure | $m | [22.4](/filings/0001193125-26-216791.md) | [21.7 d](/filings/0001193125-26-349185.md) | [0.3](/filings/0001193125-26-216791.md) | [0.3 d](/filings/0001193125-26-349185.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.8](/filings/0001193125-26-216791.md) | [2.8](/filings/0001193125-26-349185.md) | [33.7](/filings/0001193125-26-216791.md) | [54.1](/filings/0001193125-26-349185.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 54,165,030 at 2026-08-03, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349185.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.